Latest developments, interviews and media coverage
16.06.2025
Venture aims to develop therapeutics based on preclinical findings that blocking a hormone produced by fat cells protects mice from a wide array of metabolic and inflammatory disorders, including obesity, asthma, and cardiovascular disease
Read More16.06.2025
Gökhan Hotamışlıgil, James Stevens Simmons Professor of Genetics and Metabolism at the Harvard T.H. Chan School of Public Health, said, “This funding will provide support and momentum for our efforts to develop solutions for obesity and age-related diseases.”
Read More16.06.2025
İş Private Equity provides funding to develop new therapies for obesity and age-related diseases: Enlila biotech venture announced
Read More31.01.2026
“I was very pleased to take part in the first episode of the ‘Girişim Sahnesi program, which aims to bring together different components of the entrepreneurship and investment ecosystem on the same stage around real experiences. On this valuable platform, launched with the support of our Bank, we had the opportunity to discuss science, innovation and the perspective of creating value on a global scale together with Prof. Dr. Gökhan Hotamışlıgil. We also talked about the story behind Enlila, a venture established through our subsidiary İş Private Equity in collaboration with the Hotamışlıgil Laboratory at the Harvard T.H. Chan School of Public Health, which aims to develop solutions for chronic diseases associated with aging and obesity.”
Hakan Aran, CEO, İşbank